Ernexa Therapeutics (NASDAQ:ERNA) Shares Set to Reverse Split on Monday, May 4th

Shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) are set to reverse split on the morning of Monday, May 4th. The 1-25 reverse split was announced on Thursday, April 30th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, May 1st.

Ernexa Therapeutics Price Performance

Shares of Ernexa Therapeutics stock traded down $0.04 on Thursday, hitting $0.15. 2,009,922 shares of the company’s stock traded hands, compared to its average volume of 1,442,568. The company has a fifty day moving average of $0.24 and a two-hundred day moving average of $0.88. Ernexa Therapeutics has a one year low of $0.13 and a one year high of $4.02. The company has a market capitalization of $4.30 million, a price-to-earnings ratio of -0.05 and a beta of 6.79.

Ernexa Therapeutics (NASDAQ:ERNA) last released its earnings results on Friday, March 13th. The company reported ($0.01) EPS for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Ernexa Therapeutics currently has a consensus rating of “Sell”.

Institutional Trading of Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. 70.55% of the stock is owned by hedge funds and other institutional investors.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.